Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02156076 · ClinicalTrials.gov registry record · Phase 2
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT02156076 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 158 participants.
The verdict
NCT02156076, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF) through its effect on AF burden (AFB), or the percent of time in AF, in subjects with paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg QD, 12 mg QD following a 1-week period of loading doses of 3 mg QD, 8 mg QD and 20 mg QD, respectively) for a total of 4 weeks. It is hypothesized that treatment with BMS-919373 will reduce AF burden as compared to baseline relative to placebo.
Interventions
- DRUG BMS-919373
- DRUG Placebo (Matching with BMS-919373)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2014-07-25 |
| Est. Completion | 2016-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02156076
The ClinicalTrials.gov registry entry for NCT02156076 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-919373 is the first listed.
NCT02156076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02156076 about?
NCT02156076 is a clinical study titled "A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation". The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF) through its effect on AF burden (AFB), or the percent of time in AF, in subjects with paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg QD, 12 mg QD following a 1-...
What is the current status of trial NCT02156076?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2014-07-25. Estimated completion is 2016-06-01.
What interventions are being tested in trial NCT02156076?
The interventions under investigation include: BMS-919373 (DRUG), Placebo (Matching with BMS-919373) (DRUG).
Who is sponsoring clinical trial NCT02156076?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.